Table 3.
Univariate and multivariate analysis in the population of patients with sarcomatoid differentiation
| Overall survival (Overall population) | Univariate Cox Regression | Multivariate Cox Regression | ||
|---|---|---|---|---|
| HR (95% CI ) | p value | HR (95% CI ) | p value | |
| Sex (females vs. males) | 1.95 (1.31 − 2.90) | 0.001 | 1.72 (1.15 − 2.57) | 0.008 |
| Age (≥ 70y vs. < 70y) | 1.52 (1.01 − 2.28) | 0.045 | 1.64 (1.07 − 2.51) | 0.022 |
| BMI (> 25 vs. ≤ 25) | 0.93 (0.63 − 1.38) | 0.732 | ||
| Nephrectomy (yes vs. no) | 0.48 (0.31 − 0.75) | 0.001 | 0.74 (0.47 − 1.17) | 0.199 |
| Histology (nccRCC vs. ccRCC) | 1.04 (0.81 − 1.32) | 0.773 | ||
| IMDC group (poor vs. intermediate) | 2.13 (1.46 − 3.10) | < 0.001 | 2.13 (1.42 − 3.19) | < 0.001 |
| Number of metastatic sites (> 2 vs ≤ 2) | 1.19 (0.80 − 1.78) | 0.382 | ||
| Lung metastases (yes vs. no) | 0.87 (0.57 − 1.33) | 0.519 | ||
| Lymph node metastases (yes vs. no) | 1.09 (0.84 − 1.41) | 0.505 | ||
| Bone metastases (yes vs. no) | 1.75 (1.18–2.60) | 0.005 | 1.62 (1.08–2.43) | 0.021 |
| Liver metastases (yes vs. no) | 1.82 (1.18 − 2.80) | 0.006 | 1.78 (1.15–2.75) | 0.010 |
| Brain metastases (yes vs. no) | 1.61 (0.91 − 2.83) | 0.101 | ||
BMI = Body Mass Index; ccRCC = clear cell Renal Cell Carcinoma; IMDC = International Metastatic RCC Database Consortium; nccRCC = non-clear cell Renal Cell Carcinoma